MAY 28, 2026 – Thousands of Zantac-related lawsuits have been filed in the United States alleging links between ranitidine use and cancer diagnoses. On April 13, 2026, a state court in Delaware dismissed over 80,000 lawsuits filed against Zantac manufacturer Boehringer Ingelheim that claimed the company’s popular heartburn medication caused cancer.
People who developed certain cancers after using Zantac may qualify to file a Zantac lawsuit in the United States. Most claims involve allegations of an active ingredient found in Zantac called ranitidine. This ingredient could form unsafe levels of NDMA, a chemical classified as a probable human carcinogen.
Understanding who qualifies for a Zantac lawsuit is important for individuals seeking compensation for medical expenses, lost wages, pain and suffering, and other damages.
Let’s learn more about this eligibility and other frequently asked questions for Zantac lawsuits that can affect the claims.
What Made Zantac Legally Problematic
The active component of Zantac, ranitidine, shows chemical instability. The medication becomes hazardous without requiring any external substances to enter its system. Researchers discovered that ranitidine undergoes natural degradation into NDMA, which occurs at an accelerated rate when the drug exists in warm and humid storage environments that people use to store their medications.
The discovery process of the internal documents revealed that manufacturers had known about ranitidine’s unstable nature since the product existed. The plaintiffs assert that the defendant chose to hide this information instead of providing it to both the FDA and consumers.
A 2024 study published in the Journal of Pharmaceutical and Biomedical Analysis Open confirmed that common storage conditions significantly increase NDMA levels in ranitidine products, providing scientific support for claims that ordinary consumer behavior contributed to elevated carcinogen exposure.
Plaintiffs in Zantac lawsuits base their legal arguments on the failure-to-warn legal principle, which demonstrates that manufacturers should have disclosed to consumers their knowledge that ranitidine would transform into a carcinogenic substance.
The November 2024 jury reached a deadlock on causation regarding one plaintiff’s bladder cancer, yet they reached a unanimous decision that Boehringer Ingelheim had not provided sufficient consumer warnings, which now serves as important evidence for ongoing cases.
The Four Criteria That Determine Eligibility
1. You Used Brand-Name Zantac Containing Ranitidine
The lawsuits target ranitidine-based Zantac specifically. The newer Zantac 360 formulation uses famotidine instead of ranitidine and is not part of this litigation. Generic ranitidine products follow a separate legal framework based on innovator liability, which some state courts allow while other state courts do not.
You can provide proof like prescription records, pharmacy records, purchase receipts, or physician documentation. These will serve as the strongest evidence of qualifying product use. The primary candidate pool consists of people who regularly used Zantac, whether over-the-counter or by prescription, before the April 2020 recall.
2. You Were Diagnosed With a Qualifying Cancer
The cancers most consistently accepted in Zantac litigation are those with documented links to NDMA exposure. Bladder cancer establishes the strongest scientific connection, which has produced the most beneficial court decisions for plaintiffs. The broader list of cancers that courts and settlement structures have recognized includes bladder, stomach, esophageal, liver, pancreatic, kidney, colorectal, and breast cancer.
Some courts have also allowed claims for lung cancer. Prostate cancer cases face greater opposition because judges need to balance weak epidemiological evidence and divided jury results from recent courtroom battles.
Each cancer type receives different degrees of scientific evidence that connects NDMA to its respective links. In December 2022, a federal court dismissed all federal cases because the plaintiffs’ experts could not meet the expert testimony standard for general causation in federal court.
State courts have applied different standards, and most active litigation is now proceeding in Delaware, Illinois, California, and Pennsylvania state courts.
3. The Timing of Your Diagnosis Falls Within the Recognized Window
The medical identification of cancer must connect back to the time period when Zantac was consumed. The GSK litigation established settlement frameworks that use a 20-year period, starting from the final Zantac consumption, as the maximum time frame for recognized medical conditions.
The diagnosis must also have occurred before the claimant reached age 89. Courts examine whether the cancer developed during the defendant’s active usage period or after that time or before any substantial contact began.
4. No Disqualifying Pre-Existing Conditions
Some existing medical conditions will hinder or nullify a claim when they function as separate medical causes of the diagnosed cancer. The defendants presented hepatitis B, hepatitis C, H. pylori infection, and achalasia as alternative cancer causes. Plaintiffs have linked them to NDMA exposure.
Not all claimants with one of these conditions will be disqualified. Nevertheless, the pre-existing condition affects the strength and value of the claim and must be carefully evaluated from a legal and medical perspective.
What the Current Litigation Landscape Means for New Claimants
The current level of settlement activity does not provide evidence that the legal proceedings have reached their conclusion. The GSK settlement resolved approximately 93% of pending state court cases, but lawsuits against Boehringer Ingelheim continue through trial. People who took Zantac for many years are linking their cancer diagnoses to their medication history. This results in new cases being filed.
A New Jersey man filed in June 2025 alleging that three decades of ranitidine use caused his prostate, kidney, and bladder cancer.
The Delaware Supreme Court issued a significant ruling in 2024 that established stricter requirements for expert testimony in Zantac cases. The ruling requires plaintiffs to prove that their cancer developed through specific ranitidine exposure instead of using general NDMA research. This raises the bar for some claim types.
The state filing deadlines continue to operate. The statute of limitations period, which varies by state, allows claimants to file their claims within two to three years from either their cancer diagnosis date or the point when they should have linked their diagnosis to Zantac usage.
Eligibility Turns on Documentation and Timing
Zantac litigation currently progresses through multiple ongoing legal proceedings, which include active trials and defendants who have not yet reached settlements and parties who continue to bring new claims.
The people most likely to have viable claims are those with documented long-term use of ranitidine-based Zantac before the 2020 recall who have obtained a cancer diagnosis that medical research has established as linked to NDMA exposure and who possess no medical evidence that cancels the association between the drug and their cancer diagnosis.
The evidence of use together with the evidence of harm must establish connections across a timeline that extends through multiple decades to establish a claim as actionable. The past two decades of pharmacy records, together with old prescription bottles and medical records that show Zantac use during treatment, can all function as valid proof.
The development of NDMA-induced cancers requires multiple years to reach a stage where they first show symptoms.